Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Abstract Background The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has emerged as a promising new target for cancer therapeutics, with lasting responses seen in the treatment of metastatic renal and lung carcinomas, as well as melanomas. As tumor surface express...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-06-01
|
| Series: | Diagnostic Pathology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13000-017-0631-6 |
| _version_ | 1819236929576632320 |
|---|---|
| author | Opal L. Reddy Peter I. Shintaku Neda A. Moatamed |
| author_facet | Opal L. Reddy Peter I. Shintaku Neda A. Moatamed |
| author_sort | Opal L. Reddy |
| collection | DOAJ |
| description | Abstract Background The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has emerged as a promising new target for cancer therapeutics, with lasting responses seen in the treatment of metastatic renal and lung carcinomas, as well as melanomas. As tumor surface expression of PD-L1 has been found to correlate with objective responses to anti-PD-L1 immunotherapies, we investigated the expression of PD-L1 in human cervical tumors and provide an adopted scoring system for the systematic evaluation of PD-L1 staining. Methods Immunohistochemical staining for PD-L1 expression was performed on a tissue microarray of 101 normal and neoplastic cervical tissues. Neoplastic cores were divided into three groups: squamous cell carcinoma, adenosquamous carcinoma, and endocervical adenocarcinoma. PD-L1 expression was scored based on an adopted scoring system accounting to percentage and intensity of positivity, and results provided alongside available clinical and demographic data. Results Overall, PD-L1 was positive in 32 of 93 (34.4%) cervical carcinomas. Subcategorically, PD-L1 was positive in 28 of 74 (37.8%) squamous cell carcinomas, two of seven (28.6%) adenosquamous carcinomas, and two of 12 (16.7%) endocervical adenocarcinomas. It was negative in six benign cervical tissues. Conclusions This study shows a significant expression of PD-L1 in 34.4% of cervical carcinomas and no expression of PD-L1 in benign cervical tissues. These findings suggest a role for further investigation of anti-PD-L1/PD-1 immunotherapies in the treatment of PD-L1-positive cervical tumors. In addition, our adopted scoring system will facilitate more systematic correlations between tumor reactivity and response to treatment. |
| first_indexed | 2024-12-23T13:12:15Z |
| format | Article |
| id | doaj.art-caa1716f7bb84a8a9d05b13c5354feb5 |
| institution | Directory Open Access Journal |
| issn | 1746-1596 |
| language | English |
| last_indexed | 2024-12-23T13:12:15Z |
| publishDate | 2017-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Diagnostic Pathology |
| spelling | doaj.art-caa1716f7bb84a8a9d05b13c5354feb52022-12-21T17:45:42ZengBMCDiagnostic Pathology1746-15962017-06-0112111110.1186/s13000-017-0631-6Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomasOpal L. Reddy0Peter I. Shintaku1Neda A. Moatamed2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLADepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLADepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLAAbstract Background The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has emerged as a promising new target for cancer therapeutics, with lasting responses seen in the treatment of metastatic renal and lung carcinomas, as well as melanomas. As tumor surface expression of PD-L1 has been found to correlate with objective responses to anti-PD-L1 immunotherapies, we investigated the expression of PD-L1 in human cervical tumors and provide an adopted scoring system for the systematic evaluation of PD-L1 staining. Methods Immunohistochemical staining for PD-L1 expression was performed on a tissue microarray of 101 normal and neoplastic cervical tissues. Neoplastic cores were divided into three groups: squamous cell carcinoma, adenosquamous carcinoma, and endocervical adenocarcinoma. PD-L1 expression was scored based on an adopted scoring system accounting to percentage and intensity of positivity, and results provided alongside available clinical and demographic data. Results Overall, PD-L1 was positive in 32 of 93 (34.4%) cervical carcinomas. Subcategorically, PD-L1 was positive in 28 of 74 (37.8%) squamous cell carcinomas, two of seven (28.6%) adenosquamous carcinomas, and two of 12 (16.7%) endocervical adenocarcinomas. It was negative in six benign cervical tissues. Conclusions This study shows a significant expression of PD-L1 in 34.4% of cervical carcinomas and no expression of PD-L1 in benign cervical tissues. These findings suggest a role for further investigation of anti-PD-L1/PD-1 immunotherapies in the treatment of PD-L1-positive cervical tumors. In addition, our adopted scoring system will facilitate more systematic correlations between tumor reactivity and response to treatment.http://link.springer.com/article/10.1186/s13000-017-0631-6Uterine cervixCervical cancerSquamous cell carcinomaEndocervical adenocarcinomaAdenosquamous carcinomaPD-L1 |
| spellingShingle | Opal L. Reddy Peter I. Shintaku Neda A. Moatamed Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas Diagnostic Pathology Uterine cervix Cervical cancer Squamous cell carcinoma Endocervical adenocarcinoma Adenosquamous carcinoma PD-L1 |
| title | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| title_full | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| title_fullStr | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| title_full_unstemmed | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| title_short | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| title_sort | programmed death ligand 1 pd l1 is expressed in a significant number of the uterine cervical carcinomas |
| topic | Uterine cervix Cervical cancer Squamous cell carcinoma Endocervical adenocarcinoma Adenosquamous carcinoma PD-L1 |
| url | http://link.springer.com/article/10.1186/s13000-017-0631-6 |
| work_keys_str_mv | AT opallreddy programmeddeathligand1pdl1isexpressedinasignificantnumberoftheuterinecervicalcarcinomas AT peterishintaku programmeddeathligand1pdl1isexpressedinasignificantnumberoftheuterinecervicalcarcinomas AT nedaamoatamed programmeddeathligand1pdl1isexpressedinasignificantnumberoftheuterinecervicalcarcinomas |